2023 ASCO Highlights

 

Learn more about key Dana-Farber research studies on Prostate, Kidney, Bladder, Breast, and Ovarian Cancer.

News Releases: 

Resources: 


ASCO 2023: Glioma Research Presented by Patrick Wen, MD

The first phase 3 clinical trial of a molecularly targeted therapy for low grade IDH-mutant glioma showed positive results and opens the door to new possibilities for patients.
Patrick Wen, MD

Patrick Wen, MD

Neuro-oncology

ASCO 2023: Breast Cancer Research Presented by Sara Tolaney, MD

Data shows antibody-drug conjugate offers significant survival benefit for patients with HR-positive/HER2-negative metastatic breast cancer.
Sara Tolaney, MD, MPH

Sara Tolaney, MD, MPH

Medical Oncology

ASCO 2023: Kidney Cancer Research Presented by Toni Choueiri, MD

We learn from negative study results as well as from positive ones. Phase 3 study by Dana-Farber's Toni Choueiri, MD, shows that rechallenge with PD-L1 inhibitors in second-line therapy for advanced kidney cancer has no benefit.
Toni Choueiri, MD

Toni Choueiri, MD

Medical Oncology

ASCO 2023: Breast Cancer Research Presented by Paolo Tarantino, MD

Data from more than 8,000 patients with stage 1A triple-negative breast cancer finds improved 5-year breast-cancer specific survival in those treated with adjuvant chemotherapy whose tumors measured between 1-2 cm.

ASCO 2023: Prostate Cancer Research Presented by Praful Ravi, MB BCHIR, MRCP

ICECAP collaboration was the largest study looking at the prognostic value of PSA nadir in localized prostate cancer, finding a PSA level of less than 0.1 could provide an early prognosis signal.

ASCO 2023: Treating NUT Carcinoma Research Presented by Jia Luo, MD

Dana-Farber's Jia Luo, MD, details on findings from the NUT Carcinoma Registry on initial chemotherapy for locally advanced and metastatic disease.
Jia Luo, MD

Jia Luo, MD

Medical Oncology

ASCO 2023: Head And Neck Research Presented by Glenn Hanna, MD

Encouraging anti-tumor activity for patients with metastatic head & neck squamous cell carcinoma who are HPV-negative and treated with bifunctional EGFR/TGF-beta inhibitor BCA101 w/pembrolizumab.
Glenn Hanna, MD

Glenn Hanna, MD

Medical Oncology

ASCO 2023: Breast Cancer Research Presented by Jennifer Ligibel, MD

Women with breast cancer shed pounds thanks to telephone-based weight loss program, clinical trial finds.
Jennifer Ligibel, MD

Jennifer Ligibel, MD

Medical Oncology

ASCO 2023: Bladder Cancer Highlights Presented By Charlene Mantia, MD

The Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute presents a succinct summary of all the bladder cancer clinical updates you need to know from ASCO 2023.
Charlene Mantia, MD

Charlene Mantia, MD

Medical Oncology
Joaqium Bellmunt, MD, PhD

Joaqium Bellmunt, MD, PhD

Medical Oncology

ASCO 2023: Kidney Cancer Highlights Presented By Vincent (Wenxin) Chu, MD

The Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute presents a succinct summary of all the kidney cancer clinical updates you need to know from ASCO 2023.
Wenxin Xu, MD

Wenxin Xu, MD

Medical Oncology
Toni Choueiri, MD

Toni Choueiri, MD

Medical Oncology

ASCO 2023: Prostate Cancer Highlights Presented By Jacob Berchuck, MD

The Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute presents a succinct summary of all the prostate cancer clinical updates you need to know from ASCO 2023.
Jacob Berchuck, MD

Jacob Berchuck, MD

Medical Oncology
Mary-Ellen Taplin, MD

Mary-Ellen Taplin, MD

Medical Oncology